Warner-lambert Company

William Chester Patt

Harriet W Hamilton

Joseph Thomas Repine

Annette M Doherty

Nicole Chantel Barvian

Ila Sircar

Patrick Michael O'Brien

Xue-min Cheng

David T Connor

Drago R Sliskovic

Bharat Kalidas Trivedi

Cleo Connolly

Joseph Armand Picard

John C Hodges

James S Kaltenbronn

Michael William Wilson

Jeremy John Edmunds

Daniel Fred Ortwine

Mark Stephen Plummer

Kent A Berryman

Richard Dennis Dyer

Kevon Ray Shuler

Richard Himmelsbach

Bill R Reisdorph

Adam Richard Johnson

Bruce D Roth

Mark A Massa

Walter H Moos

Helen Tsenwhei Lee

Annette Marian Doherty

Timothy R Hurley

Kimberly Suzanne Para

Michael James Lovdahl

Melean Visnick

Christine Nylund Kolz

Mark Alan Massa

Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein:

Isophthalic acid derivatives as matrix metalloproteinase inhibitors

The present invention provides compounds of Formula I wherein W, Q, E, D, R, R, R, Y, K, R, R, R, G, and the double bond denoted '*' have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

Benzoxazin-3-ones and derivatives thereof as therapeutic agents

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,wherein:

Pyridine matrix metalloproteinase inhibitors

Selective MMP-13 inhibitors are isophthalic acid derivatives of the formulawherein:

Selective MMP-13 inhibitors are pyrimidine derivatives of the formulaor a pharmaceutically acceptable salt thereof,

Pyrimidine matrix metalloproteinase inhibitors

The present invention provides compounds of formula (I) wherein R, Z, Y, W, R, V, and X are as defined in the description, and pharmaceutically acceptable salts thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

1,2,4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,

Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors

Sulfonamide matrix metalloproteinase inhibitors

Novel nonpeptide endothelin I antagonists of Formula

Nonpeptide endothelin antagonists with increased water solubility

Endothelin antagonists with ether-linked groups

Ketoacid endothelin antagonists

Novel nonpeptides characterized as having a carbamic group which are antagonists of endothelin I are described, as well as methods for their preparation and pharmaceutical compositions containing the same. The compounds are useful in treating elevated levels of endothelin and are therefore useful in the treatment of hypertension, myocardial infarction, diabetes, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythminas, asthma, chronic and acute renal failure, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, stroke, head injury, and ischemic bowel syndrome.

Butenolide endothelin antagonists

Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.

Nonpeptide endothelin antagonists I

The present invention provides compounds having the Formula I ##STR1## The present invention also provides methods of treating atherosclerosis, coronary heart disease, and restenosis using the compounds of Formula I, and pharmaceutical compositions comprising the compounds of Formula I.

Phenyl glycine compounds and methods of treating atherosclerosis and

Growing community of inventors

Chelsea, MI, United States of America

William Chester Patt